To the full analysis
LNA Santé stock: growth
LNA.PALNA Santé reported $1.01B in revenue for fiscal 2025, up 13.1% on the prior year, up 9.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
14.1%
per year from 2006 to 2025, per share 11.8%
Earnings (Annual rate)
13.1%
per year from 2006 to 2025, per share 10.7%
Free cash flow (Annual rate)
15%
per year from 2006 to 2025, per share 12.7%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 9.7% | 7.9% | 14.1% |
| Revenue per share | 8.2% | 6.3% | 11.8% |
| Earnings | 25.3% | 8.6% | 13.1% |
| Earnings per share | 23.7% | 7.0% | 10.7% |
| Free cash flow | −14.9% | 20.9% | 15.0% |
| Free cash flow per share | −16.0% | 19.0% | 12.7% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $82.17M | $2.6M | $4.58M |
| 2007 | $133.52M | $3.8M | $9.15M |
| 2008 | $174.9M | $5.5M | $1.5M |
| 2009 | $223.68M | $6.86M | $16.14M |
| 2010 | $228.5M | $9.13M | $31.1M |
| 2011 | $245.53M | $9.21M | $5.92M |
| 2012 | $286.86M | $6.9M | −$12.23M |
| 2013 | $359.21M | $8.55M | $18.15M |
| 2014 | $394.68M | $7.79M | −$1.54M |
| 2015 | $470.74M | $11.77M | $9.89M |
| 2016 | $526.37M | $23.96M | $25.24M |
| 2017 | $539.28M | $26.84M | $59.16M |
| 2018 | $597M | $23.85M | $42.63M |
| 2019 | $584.92M | $23.08M | $123.56M |
| 2020 | $635.93M | $8.65M | $147.09M |
| 2021 | $764.03M | $26.05M | $73.11M |
| 2022 | $806.95M | $28.6M | $99.57M |
| 2023 | $815.66M | $25.94M | $93.7M |
| 2024 | $893.8M | $24.17M | $78.94M |
| 2025 | $1.01B | $26.76M | $65.71M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Feb 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.